Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Oncology Center of Excellence

Oncology Center of Excellence

                        Who We Are - Oncology Center of Excellence
          Project Patient Voice


                        OCE Annual Reports
          Project Community Home
          About FDA
          FDA Organization
          Oncology Center of Excellence
          Project Significant: Statistics in Cancer TrialsOncology Center of Excellence Project Significant: Statistics in Cancer Trials
  
  					Promoting collaboration in design and analysis of cancer clinical trials
	
    Share
    Post
    Linkedin

    Email
    PrintImage
              Project Significant**Project Significant (*Statistics in Cancer Trials*)** established by the FDA Oncology Center of Excellence, promotes collaboration and engagement among diverse stake holders to further the design and analysis of cancer clinical trials with the goal to advance cancer therapies.

Project Significant objectives:

Provides a platform to participate, discuss, and advance the science of oncology trial designs.
	Promotes non-product specific scientific discussions on design and analysis of cancer clinical trials.
	Fosters collaboration among regulators (US and international), professional organizations, industry, academicians, and patients to advance cancer therapies with improved design of cancer clinical trials.In October 2020, Project Significant began a collaboration with the Biopharmaceutical Section (BIOP) of American Statistical Association (ASA) to hold scientific discussions with diverse stakeholders who understand the unique aspects of oncology clinical trials. The topic for the first meeting was, “Type I error considerations in Master Protocols with common control in oncology clinical trials.” Additional discussions, approximately once a month, may inform and enlighten the design and analysis of future oncology clinical trials. These virtual discussions are organized jointly by the ASA BIOP Statistical Methods in Oncology Scientific Working Group, the FDA Oncology Center of Excellence, and LUNGevity Foundation, and hosted by ASA.

Project Significant collaborates not only among academia and industry but among international regulators. This informal academic collaboration can pave a path for cancer patients to receive earlier access to products through more efficient clinical trial designs, conduct, and analyses. Pivotal clinical trials in oncology are commonly conducted internationally and these global trials are important for investigating the safety and effectiveness of cancer therapies. Future cancer therapy developments can be speeded by understanding the complex issues in conducting cancer trials and bringing common understanding among all the stakeholders involved in the development of cancer therapies through improved clinical trial designs.

**The Team**

Rajeshwari Sridhara, PhD, Oncology Center for Excellence,
	Richard Pazdur, Director, OCE
	Marc Theoret, Deputy Director, OCEProject Management: Joan Ferlo Todd, RN, Senior Regulatory Health Scientist, OCE

**Publications**

Sridhara R, Marchenko O, Jiang Q, et.al. Use of Non-concurrent Common Control for Treatment Comparisons in Master Protocols. Biopharmaceutical Report, 2021, Vol. 28, No. 1, 12-14.
	Barksdale E, Sridhara R, Marchenko O, et al. Summary of American Statistical Association Biopharmaceutical Section’s Virtual Discussions with Regulators on Statistical Considerations in Oncology Trials in the COVID-19 Era. Biopharmaceutical Report, 2021, Vol. 28, No. 3, pp 23-25.
	Marchenko O, Sridhara R, Jiang Q, et.al. Summary of ASA Virtual Discussion with Regulators on Designing Dose-Optimization Studies in Cancer Drug Development. Biopharmaceutical Report, 2021, Vol. 28, No. 3, 26-27.
	Sridhara R, Marchenko O, Jiang Q, et.al. Summary of American Statistical Association Biopharmaceutical Section’s Virtual Discussions with Regulators on Evaluation of Treatment Effect in Underrepresented Population in Oncology Clinical Trials. Biopharmaceutical Report, 2021, Vol. 28, No. 3, pp 28-30.
	Sridhara R, Marchenko O, Jiang Q, et al. Type I Error Considerations in Master Protocols With Common Control in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion. Statistics in Biopharmaceutical Research, 2022, Vol. 14 No. 3, 348-352.
	Sridhara R, Marchenko O, Jiang Q, et.al. Use of Nonconcurrent Common Control in Master Protocols in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion. Statistics in Biopharmaceutical Research, 2022, Vol. 14 No. 3, 353-357.
	Sridhara R, Marchenko O, Jiang Q, et.al. Summary of ASA Virtual Discussion with Regulators on Statistical Considerations in Clinical Trials for Rare Pediatric Cancers. Biopharmaceutical Report, 2022, Vol. 29, No 1, 30-32.
	Sridhara R, Marchenko O, Jiang Q, et. al. Summary of American Statistical Association Biopharmaceutical Section’s Virtual Discussion with Regulators on Time-to Event Endpoints in Cancer Trials in the Presence of Non-proportional Hazards, Biopharmaceutical Report, 2022, Vol. 29, No. 2, 42-44.
	Sridhara R, Marchenko O, Jang Q, et. al. Summary of ASA BIOP Section’s Virtual Discussion with Regulators on Consideration of Bayesian Approaches in Pediatric Cancer Clinical Trials. Biopharmaceutical Report, 2022, Vol. 29, No. 3, 45-46.
	Sridhara R, Marchenko O, Jang Q, et. al. Summary of ASA BIOP Section’s Virtual Discussion with Regulators on Considerations for Data Monitoring Committee and Regulator Direct Interactions in Ongoing Randomized Cancer Clinical Trials. Biopharmaceutical Report, 2022, Vol. 29, No. 3, 47-49.
	Sridhara R, Barksdale E, Marchenko O, et al. Cancer Clinical Trials Beyond Pandemic: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion. Statistics in Biopharmaceutical Research, 2023, Vol. 15 No. 2, 4444-449.
	Sridhara R, Marchenko O, Jang Q, et al. Letter to Editor. Evaluation of Treatment Effect in Underrepresented Populations in Cancer Trials: Discussion with International Regulators. Statistics in Biopharmaceutical Research, 2023, Vol. 15 No. 2, 450-456.
	Marchenko O, Sridhara R, Jang Q, et. al. Letter to Editor. Designing Dose-Optimization Studies in Cancer Drug Development: Discussions with Regulators. Statistics in Biopharmaceutical Research, 2023, Feb 14 online pp 1-7.**For Further Information**

Oncology Regulatory Affairs
	Office of Oncologic Diseases (OOD)
	Project Orbis
	Oncology Center of Excellence

                                                                                  Content current as of:
      06/20/2023Oncology Center of Excellence

          
                        Who We Are - Oncology Center of Excellence
          Project Patient Voice


                        OCE Annual Reports
          Project Community
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop